Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aclerastide
- Development stage
- Discontinued
- Lead developer
- Integra LifeSciences
- Modality
- Peptides, Small Molecules
- Administration
- Topical
01
Overview
Aclerastide is a synthetic peptide analog of angiotensin 1–7, developed primarily for the treatment of diabetic foot ulcers and other chronic wounds. It acts as an agonist at the MAS1 receptor (the receptor for angiotensin 1–7), functioning as an angiotensin receptor agonist and stem cell stimulant. Its mechanism involves induction of progenitor cell proliferation, accelerated vascularization, collagen deposition, and re-epithelialization at wound sites. Preclinical studies showed enhanced wound healing compared to existing therapies such as becaplermin. However, clinical development was discontinued after failing to meet efficacy endpoints in phase III trials for diabetic foot ulcer treatment[1][3][4][5][6][8]. The drug was developed by Derma Sciences (a subsidiary of Integra LifeSciences), with involvement from the University of Southern California and US Biotest Inc[3].
- Brand names
- aclerastide
- Other names
- [Nle3]-Angiotensin II (1–7)
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)MAS1 (Mas receptor)
Beyond the preview
Go deeper on aclerastide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aclerastide.